About: CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
Creator	Huang, He Zhang, Xi Yang, Li Li, Yuhua Blaise, Didier Mohty, Mohamad Wei, Guoqing Liang, Aibin Tan, Elaine Nagler, Arnon Su, Junwei Zhou, Jianfeng Cui, Qu Fu, Shan Hu, Yongxian Jin, Aiyun Jing, Hongmei Qiu, Lugui Wu, Hengwei Yang, Yingying Yin, Su
Source	Elsevier; Medline; PMC
abstract	The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
has issue date	2020-06-28(xsd:dateTime)
bibo:doi	10.1016/j.retram.2020.06.003
bibo:pmid	32620465
has license	no-cc
sha1sum (hex)	defdb4d85eddc245cb4744c5b2e32bbeda8e6c58
schema:url	https://doi.org/10.1016/j.retram.2020.06.003
resource representing a document's title	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
has PubMed Central identifier	PMC7321051
has PubMed identifier	32620465
schema:publication	Curr Res Transl Med
resource representing a document's body	covid:defdb4d85eddc245cb4744c5b2e32bbeda8e6c58#body_text
is schema:about of	named entity 'refractory' named entity 'COVID-19' named entity 'synergistic' named entity 'Affiliated Hospital' named entity 'refractory' named entity 'CAR-T therapy' named entity 'axicabtagene ciloleucel' named entity 'retrospective study' named entity 'CAR-T' named entity 'tocilizumab' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'hematological malignancies' named entity 'T-cell' named entity 'Genetically engineered' named entity 'COVID' named entity 'refractory' named entity 'CAR-T' named entity 'coronavirus' named entity 'CAR-T' named entity 'infection' named entity 'allogeneic' named entity 'status quo' named entity 'COVID-19' named entity 'interleukins' named entity 'inflammatory factors' named entity '28 days' named entity 'IgM' named entity 'CAR-T' named entity 'fever' named entity 'remission' named entity 'COVID' named entity 'steroids' named entity 'hematologic malignancies' named entity 'CAR-T' named entity 'life-threatening' named entity 'refractory' named entity 'pneumonia' named entity 'cytokine storm' named entity 'PCR' named entity 'cryopreserved' named entity 'nucleic acid tests' named entity 'nasopharyngeal swab' named entity 'health services' named entity 'crowded places' named entity 'COVID-19 pandemic' named entity 'refractory' named entity 'acute lymphocytic leukemia' named entity 'pulmonary function tests' named entity 'alveolar epithelial cells' named entity 'infection' named entity 'fatigue' named entity 'IL-7' named entity 'pro-inflammatory cytokine' named entity 'clinical outcomes' named entity 'leukapheresis' named entity 'CAR-T' named entity 'assay' named entity 'B-cell' named entity 'autologous' named entity 'B-cell malignancies' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software